|
1
|
Soeda M, Ohka S, Nishizawa D, Iseki M, Yamaguchi K, Arita H, Hanaoka K, Kato J, Ogawa S, Hiranuma A, Hasegawa J, Nakayama K, Ebata Y, Hayashida M, Ichinohe T, Fukuda KI, Ikeda K. Single-Nucleotide Polymorphisms of the PAR2 and IL-17A Genes Are Significantly Associated with Chronic Pain. Int J Mol Sci 2023; 24:17627. [PMID: 38139455 PMCID: PMC10744199 DOI: 10.3390/ijms242417627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/10/2023] [Accepted: 12/14/2023] [Indexed: 12/24/2023] Open
Abstract
Patients with chronic pain are affected psychologically and socially. There are also individual differences in treatment efficacy. Insufficient research has been conducted on genetic polymorphisms that are related to individual differences in the susceptibility to chronic pain. Autoimmune disorders can lead to inflammation and chronic pain; therefore, we focused on the autoimmune-related protease-activated receptor 2 (PAR2/F2RL1) and interleukin 17A (IL-17A/IL17A) genes. PAR2 and IL-17A are associated with autoimmune diseases that lead to chronic pain, and PAR2 regulates T-helper (Th) cell activation and differentiation. We hypothesized that the PAR2 and IL-17A genes are associated with chronic pain. The present study used a case-control design to statistically examine associations between genetic polymorphisms and the vulnerability to chronic pain. The rs2243057 polymorphism of the PAR2 gene and rs3819025 polymorphism of the IL-17A gene were previously reported to be associated with pain- or autoimmune-related phenotypes. Thus, these polymorphisms were investigated in the present study. We found that both rs2243057 and rs3819025 were significantly associated with a susceptibility to chronic pain. The present findings revealed autoimmune-related genetic factors that are involved in individual differences in chronic pain, further aiding understanding of the pathomechanism that underlies chronic pain and possibly contributing to future personalized medicine.
Collapse
Affiliation(s)
- Moe Soeda
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
- Department of Oral Health and Clinical Science, Tokyo Dental College, Tokyo 101-0061, Japan
| | - Seii Ohka
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
| | - Daisuke Nishizawa
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
| | - Masako Iseki
- Department of Anesthesiology & Pain Medicine, Juntendo University School of Medicine, Tokyo 113-8431, Japan; (M.I.)
| | - Keisuke Yamaguchi
- Department of Anesthesiology & Pain Medicine, Juntendo University School of Medicine, Tokyo 113-8431, Japan; (M.I.)
| | - Hideko Arita
- Department of Anesthesiology, Pain Relief Center, JR Tokyo General Hospital, Tokyo 151-8528, Japan; (H.A.); (K.H.)
| | - Kazuo Hanaoka
- Department of Anesthesiology, Pain Relief Center, JR Tokyo General Hospital, Tokyo 151-8528, Japan; (H.A.); (K.H.)
| | - Jitsu Kato
- Department of Anesthesiology, Nihon University School of Medicine, Tokyo 173-8610, Japan
| | - Setsuro Ogawa
- University Research Center, Nihon University, Tokyo 173-8610, Japan
| | - Ayako Hiranuma
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
- Department of Surgery, Toho University Sakura Medical Center, Chiba 285-8741, Japan
| | - Junko Hasegawa
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
| | - Kyoko Nakayama
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
| | - Yuko Ebata
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
| | - Masakazu Hayashida
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
- Department of Anesthesiology & Pain Medicine, Juntendo University School of Medicine, Tokyo 113-8431, Japan; (M.I.)
- Department of Anesthesiology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan
| | - Tatsuya Ichinohe
- Department of Dental Anesthesiology, Tokyo Dental College, Tokyo 101-0061, Japan;
| | - Ken-ichi Fukuda
- Department of Oral Health and Clinical Science, Tokyo Dental College, Tokyo 101-0061, Japan
| | - Kazutaka Ikeda
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; (M.S.); (S.O.); (D.N.)
| |
Collapse
|